Last reviewed · How we verify
NCT07064486
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
Phase 3 trial testing BGM0504 in Type 2 Diabetes (T2DM) in 477 participants. Currently enrolling.
31 July 2026
Quick facts
| Lead sponsor | BrightGene Bio-Medical Technology Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 477 |
| Start date | 4 July 2025 |
| Primary completion | 31 July 2026 |
| Estimated completion | 31 July 2026 |
| Sites | 4 locations across Indonesia |
Drugs / interventions tested
- BGM0504
- BGM0504
- Semaglutide (semaglutide) — full drug profile →
Conditions studied
- Type 2 Diabetes (T2DM) — all drugs for Type 2 Diabetes (T2DM) →
Sponsor
BrightGene Bio-Medical Technology Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Type 2 Diabetes (T2DM). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07064486
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BGM0504
Trials testing the same drug.
- NCT07166081 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight o · Phase 1 · recruiting
- NCT06929156 — A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function · Phase 1 · completed
- NCT06911203 — A Study of BGM0504 in Participants With Obesity · Phase 2 · recruiting
- NCT06920056 — A Study of BGM0504 in Overweight or Obese Participants · Phase 1 · completed
- NCT06973681 — A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects · Phase 2 · completed
Other recruiting trials for Type 2 Diabetes (T2DM)
Currently open trials in the same condition.
- NCT07246421 — Glucagon Resistance in Patients With MASLD and T2DM · NA · recruiting
- NCT07156370 — Salivary Cortisol and Hypercortisolism in Type 2 Diabetes · recruiting
- NCT07286500 — "Sexual Activity and Hypoglycemia Risk in Adults With Type 1 or Type 2 Diabetes Using Insulin Therapy and Continuous Glu · recruiting
- NCT07094529 — Personalized Hypoglycemia Outpatient Treatment - a Feasibility Study · NA · recruiting
- NCT07437157 — The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register · recruiting
Other BrightGene Bio-Medical Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT07382908 — Bioequivalence Study of BGM0504 Injection · Phase 1 · recruiting
- NCT07294235 — A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants · Phase 1 · recruiting
- NCT07239973 — A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects · Phase 1 · recruiting
- NCT07224399 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multi · Phase 1 · recruiting
- NCT07166081 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight o · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07064486 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BrightGene Bio-Medical Technology Co., Ltd.
- Last refreshed: 28 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07064486.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing